Extension usage examples:
Here's how our browser extension sees the article:
E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression - PubMed
Source: pubmed.ncbi.nlm.nih.gov
Article summary:
1. E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression by controlling the polyubiquitination level of Sestrin2 in response to leucine availability.
2. Bioinformatic analysis reveals decreased RNF167 expression and increased STAMBPL1 expression in gastric and colorectal tumors.
3. A cell-permeable peptide that blocks the STAMBPL1-Sestrin2 interaction inhibits mTORC1 and provides a potential option for cancer therapy.
Article analysis:
The article is generally reliable, as it is based on research conducted by Dong Wang et al., published in the journal Molecular Cell in February 2022. The authors have provided evidence for their claims, such as bioinformatic analysis of decreased RNF167 expression and increased STAMBPL1 expression in gastric and colorectal tumors, as well as a cell-permeable peptide that blocks the STAMBPL1-Sestrin2 interaction inhibiting mTORC1 providing a potential option for cancer therapy. The article does not appear to be biased or one-sided, as it presents both sides of the argument equally. There are no unsupported claims or missing points of consideration, as all claims are backed up with evidence from the research conducted by the authors. There are also no unexplored counterarguments or promotional content present in the article. The article does note possible risks associated with using a cell-permeable peptide to block the STAMBPL1-Sestrin2 interaction, which could potentially lead to adverse effects on mTORC1 activity. All in all, this article is trustworthy and reliable due to its lack of bias or one-sidedness, supported claims, noted risks, and lack of promotional content or unexplored counterarguments.